1. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19
- Author
-
Giustina De Silvestro, Vincenzo De Angelis, Patrizia Accorsi, Angelo Ostuni, L. Mascaretti, and Pierluigi Berti
- Subjects
Risk ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immune plasma ,Pneumonia, Viral ,Blood Donors ,030204 cardiovascular system & hematology ,Product Labeling ,Antibodies, Viral ,Article ,Donor Selection ,03 medical and health sciences ,Therapeutic approach ,Betacoronavirus ,Plasma ,0302 clinical medicine ,Immune system ,medicine ,Humans ,Intensive care medicine ,Pandemics ,Immunization Schedule ,COVID-19 Serotherapy ,Informed Consent ,Plasma derived ,Donor selection ,business.industry ,SARS-CoV-2 ,Transfusion Medicine ,Passive Immunotherapy ,Immune Sera ,Immunization, Passive ,COVID-19 ,Hematology ,Europe ,Italy ,Blood Component Removal ,Position paper ,Blood Banks ,business ,Coronavirus Infections ,030215 immunology - Abstract
Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.
- Published
- 2020